儿童系统性红斑狼疮合并血栓性微血管病的诊治与思考
收稿日期: 2024-12-30
录用日期: 2025-01-15
网络出版日期: 2025-02-12
Diagnosis, treatment, and reflection on pediatric systemic lupus erythematosus complicated by thrombotic microangiopathy
Received date: 2024-12-30
Accepted date: 2025-01-15
Online published: 2025-02-12
患儿，女，12岁，因“双下肢浮肿伴咳嗽40余天，确诊系统性红斑狼疮1个月”就诊。患儿外院肾穿刺结果提示狼疮性肾炎型（Ⅳ型）合并血栓性微血管病（TMA），经甲基泼尼松龙、环磷酰胺、贝利尤单抗治疗后，患儿仍存在重度高血压、肾功能损伤，血小板、血红蛋白、结合珠蛋白进行性下降，乳酸脱氢酶升高，外周血见破碎红细胞，入院后完善血管性血友病因子裂解酶活性正常，抗磷脂抗体阴性，可溶性c5-9明显升高。给予依库珠单抗治疗后，患儿病情好转，血红蛋白、血小板逐步回升，肾功能好转，随访病情稳定。本病例提示临床医师在系统性红斑狼疮(SLE)合并TMA治疗中，需尽早识别补体参与证据，及时启动依库珠单抗治疗，可极大改善患者远期预后。
倪佳佳 , 朱亚菊 , 金晶 , 李皎宇 , 郭桂梅 . 儿童系统性红斑狼疮合并血栓性微血管病的诊治与思考[J]. 临床儿科杂志, 2025 , 43(2) : 150 -156 . DOI: 10.12372/jcp.2025.24e1397
A 12-year-old female SLE patient with lupus nephritis (class Ⅳ) and TMA was admitted to our hospital. After treatments including blood purification, methylprednisolone and CTX pulse therapy, even belimumab infusion, she still exhibited renal dysfunction and abnormal blood tests including decreased levels in platelet count, hemoglobin and fragmented red blood cells. Further tests showed normal activity of the von Willebrand factor-cleaving protease, negative antiphospholipid antibodies, and significantly elevated soluble c5-9 levels. After initiating treatment with eculizumab, the patient's condition improved. The patient remained stable during a three-month follow-up. This case provides clinicians with insights into the treatment of SLE complicated by TMA. Early identification of complement involvement and prompt initiation of eculizumab treatment can significantly improve the patient's long-term prognosis.
| [1] | Aringer M. EULAR/ACR classification criteria for SLE[J]. Semin Arthritis Rheum, 2019, 49(3S): S14-S17. |
| [2] | Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney[J]. Clin J Am Soc Nephrol, 2018, 13(2): 300-317. |
| [3] | Bayer G, von Tokarski F, Thoreau B, et al. Etiology and outcomes of thrombotic microangiopathies[J]. Clin J Am Soc Nephrol, 2019, 14(4): 557-566. |
| [4] | Freedman SB, van de Kar N, Tarr PI. Shiga toxin-producing escherichia coli and the hemolytic-uremic syndrome[J]. N Engl J Med, 2023, 389(15): 1402-1414. |
| [5] | Mitsuiki N, Tamanuki K, Sei K, et al. Severe neonatal CMV infection complicated with thrombotic microangiopathy successfully treated with ganciclovir[J]. J Infect Chemother, 2017, 23(2): 107-110. |
| [6] | Timmermans S, Abdul-Hamid MA, Vanderlocht J, et al. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities[J]. Kidney Int, 2017, 91(6): 1420-1425. |
| [7] | National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents[J]. Pediatrics, 2004, 114(2Suppl 4th Report): 555-576. |
| [8] | Bamidele OF, Akintayo RO, Bojuwoye MO, et al. Throm-botic thrombocytopenic purpura as the first presentation in systemic lupus erythematosus[J]. Reumatologia, 2018, 56(4): 268-270. |
| [9] | Riancho-Zarrabeitia L, Martinez-Taboada V, Rua-Figueroa I, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality[J]. Lupus, 2020, 29(12): 1556-1565. |
| [10] | Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies[J]. Ther Adv Hematol, 2015, 6(4): 171-185. |
| [11] | Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative[J]. Ann Rheum Dis, 2017, 76(11): 1788-1796. |
| [12] | Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008[J]. Intern Med, 2010, 49(1): 7-15. |
| [13] | Schmidt CQ, Schrezenmeier H, Kavanagh D. Complement and the prothrombotic state[J]. Blood, 2022, 139(13): 1954-1972. |
| [14] | Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. |
| [15] | Muff-Luett M, Sanderson KR, Engen RM, et al. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study[J]. Pediatr Nephrol, 2021, 36(8): 2349-2360. |
| [16] | 中国罕见病联盟儿童非典型溶血尿毒综合征专业委员会. 中国儿童非典型溶血尿毒综合征诊治专家共识(2023版)[J]. 中华实用儿科临床杂志, 2023, 38(6): 401-412. |
| China Alliance for Rare Diseases Pediatric Atypical Hemolytic Uremic Syndrome Committee. Consensus on the diagnosis and treatment of atypical hemolytic uremic syndrome in Chinese children(2023 edition)[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2023, 38(6): 401-412. | |
| [17] | Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature[J]. Semin Arthritis Rheum, 2019, 49(1): 74-83. |
| [18] | Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study[J]. Blood, 2021, 137(18): 2438-2449. |
| [19] | Ardissino G, Possenti I, Tel F, et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update[J]. Am J Kidney Dis, 2015, 66(1): 172-173. |
| [20] | Merrill SA, Brittingham ZD, Yuan X, et al. Eculizumab cessation in atypical hemolytic uremic syndrome[J]. Blood, 2017, 130(3): 368-372. |
| [21] | Fakhouri F, Fila M, Provot F, et al. Pathogenic Variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation[J]. Clin J Am Soc Nephrol, 2017, 12(1): 50-59. |
| [22] | Fakhouri F, Schwotzer N, Fremeaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome[J]. Blood, 2023, 141(9): 984-995. |
| [23] | de Souza RM, Correa BHM, Melo PHM, et al. The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review[J]. Pediatr Nephrol, 2023, 38(1): 61-75. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
